PROSTATE-CANCER ABDOMINAL METASTASES DETECTED WITH IN-111 CAPROMAB PENDETIDE

To provide appropriate therapy for prostate cancer, accurate staging o f the patient's disease is essential, Determination of tumor size, loc ation, periprostatic extension and metastatic disease in the skeleton and soft tissue are needed to stage properly, Current diagnostic modal ities may lead to understaging in 40%-70% of prostate cancer, Detectio n of metastatic disease, both at the time of initial diagnosis and in patients with suspected local recurrence can significantly alter the t ype of therapy given, Clinical studies using the (111)ln radiolabeled immunoconjugate, MAb 7E11-C5,3-GYK-DTPA (capromab pendetide), have sho wn the superiority of radioimmunoscintigraphy over other diagnostic mo dalities in the detection of both primary and metastatic prostate canc er, Radioimmunoscintigraphy with capromab pendetide depends on express ion of tumor-associated antigen rather than lesion size, Earlier detec tion of extraprostatic invasion and metastases by means of radioimmuno scintigraphy provides valuable information for treatment decisions, A case of metastatic prostate cancer in the abdomen of a patient without local disease, in which the extent of disease was confirmed at autops y after sudden cardiac arrest, is presented.